S. cerevisiae Trm140 has two recognition modes for 3-methylcytidine modification of the anticodon loop of tRNA substrates

LU HAN, ERIN MARCUS, SONIA D'SILVA, and ERIC M. PHIZICKY

Department of Biochemistry and Biophysics, Center for RNA Biology, University of Rochester School of Medicine, Rochester, New York 14642, USA

ABSTRACT

The 3-methylcytidine (m³C) modification is ubiquitous in eukaryotic tRNA, widely found at C_{32} in the anticodon loop of tRNA^{Thr}, tRNA^{Ser}, and some tRNA^{Arg} species, as well as in the variable loop (V-loop) of certain tRNA^{Ser} species. In the yeast *Saccharomyces cerevisiae*, formation of m³C₃₂ requires Trm140 for six tRNA substrates, including three tRNA^{Thr} species and three tRNA^{Ser} species, whereas in *Schizosaccharomyces pombe*, two Trm140 homologs are used, one for tRNA^{Thr} and one for tRNA^{Ser}. The occurrence of a single Trm140 homolog is conserved broadly among Ascomycota, whereas multiple Trm140-related homologs are found in metazoans and other fungi. We investigate here how *S. cerevisiae* Trm140 protein recognizes its six tRNA substrates. We show that Trm140 has two modes of tRNA substrate recognition. Trm140 recognizes G_{35} -U₃₆-t⁶A₃₇ of the anticodon loop of tRNA^{Thr}. However, Trm140 recognition of tRNA^{Ser} substrates is different, since their anticodons do not share G_{35} -U₃₆ and do not have any nucleotides in common. Rather, specificity of Trm140 for tRNA^{Ser} is achieved by seryl-tRNA synthetase and the distinctive tRNA^{Ser} V-loop, as well as by t⁶A₃₇ and i⁶A₃₇. We provide evidence that all of these components are important in vivo and that seryl-tRNA synthetase greatly stimulates m³C modification of tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)} in vitro. In addition, our results show that Trm140 binding is a significant driving force for tRNA modification and suggest separate contributions from each recognition element for the modification.

Keywords: 3-methylcytidine; methyltransferase; modification; tRNA; specificity; anticodon loop

INTRODUCTION

tRNA undergoes extensive post-transcriptional modifications in all domains of life to ensure the efficiency and accuracy of translation. In the yeast Saccharomyces cerevisiae, each cytoplasmic tRNA has an average of 12.6 modifications, with ~10 modifications in the main body of the tRNA and ~2.6 modifications in the anticodon loop region, comprising residues N₃₂-N₃₈ of the anticodon loop and the neighboring N₃₁-N₃₉ base pair of the anticodon stem (Juhling et al. 2009). Modifications within the tRNA body often contribute to folding or stability (Helm et al. 1999; Kadaba et al. 2004; Alexandrov et al. 2006; Whipple et al. 2011). In contrast, modifications in the anticodon (primarily at the wobble nucleotide N₃₄) or at N₃₇ often contribute to accurate decoding and reading frame maintenance (Gerber and Keller 1999; Bjork et al. 2001, 2007; Urbonavicius et al. 2001; Murphy and Ramakrishnan 2004; Esberg et al. 2006; Agris et al. 2007; Waas et al. 2007; Weixlbaumer et al. 2007; Johansson et al. 2008; Chen et al. 2011; El Yacoubi et al. 2011).

Modifications occurring at other residues within the anticodon loop region also have important roles in tRNA function. For example, a yeast $pus3\Delta$ mutant, which lacks pseudouridine at U₃₈ or U₃₉, is temperature sensitive, primarily due to reduced tRNA^{Gln(UUG)} function (Han et al. 2015); and a yeast $trm7\Delta$ mutant, which lacks 2'-O-methylation at C₃₂ (Cm) as well as Gm₃₄, grows poorly due to reduced translation and reduced tRNA^{Phe} function (Pintard et al. 2002; Guy et al. 2012). N₃₂ and N₃₈ are at the borders of the anticodon loop, often form a noncanonical base pair (Auffinger and Westhof 1999), and have been shown to be critical for ribosome binding and decoding (Lustig et al. 1993; Olejniczak et al. 2005; Olejniczak and Uhlenbeck 2006; Ledoux et al. 2009).

Corresponding author: eric_phizicky@urmc.rochester.edu

Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna.059667. 116.

^{© 2017} Han et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http:// rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/ 4.0/.

The 3-methylcytidine (m³C) modification is also found at C₃₂ in the anticodon loop of tRNAs and likely has an important role. m³C is found at C₃₂ of all four characterized eukaryotic cytoplasmic tRNA^{Thr} species, 18 of the 20 characterized cytoplasmic tRNA^{Ser} species, and two of five characterized eukaryotic tRNA^{Arg} species that have an encoded C_{32} , as well as at residue e2 of the tRNA^{Ser} variable loop (V-loop) in animals (Weissenbach et al. 1977; Juhling et al. 2009; Machnicka et al. 2013; Arimbasseri et al. 2016). The m³C modification is formed by members of the Trm140 m³C methyltransferase family. In S. cerevisiae, TRM140 is required for m³C₃₂ modification of six tRNA species, including all three tRNA^{Thr} species, with anticodons IGU, CGU, and UGU, and the three tRNA^{Ser} species with anticodons CGA, UGA, and GCU (D'Silva et al. 2011; Noma et al. 2011), while tRNA^{Ser(IGA)} does not have C₃₂. In contrast, in Schizosaccharomyces pombe there are two TRM140 homologs; *trm140*⁺ is required for modification of all three tRNA^{Thr} species, whereas *trm141*⁺ is required for modification of all four tRNA^{Ser} species (Arimbasseri et al. 2016). Although S. cerevisiae trm140 Δ mutants and S. pombe mutants lacking TRM140 and/or TRM141 have no growth defect in a variety of media (D'Silva et al. 2011; Arimbasseri et al. 2016), the importance of m³C₃₂ is underscored by the growth defect of S. cerevisiae $trm140\Delta$ $trm1\Delta$ mutants in the presence of cycloheximide



FIGURE 1. The tRNA^{Thr(CGU)}_{28,50} scaffold used for analysis of tRNA^{Thr} variants is fully functional and efficiently modified to m³C. (*A*) Schematic of tRNA^{Thr(CGU)}_{28,50}. The secondary structure of tRNA^{Thr(CGU)} is shown. The base pairs of residues 28:42 and 50:64 are switched as indicated in the boxes. The primer complementary to residues 55–36 is indicated with a 3' arrow. (*B*) tRNA^{Thr(CGU)}_{28,50} is functional in vivo. $tT(CGU)\Delta$ cells containing the integrated WT tT (*CGU*) or $tT(CGU)_{28,50}$ as indicated were grown overnight in YPD medium, serially diluted and spotted onto YPD medium, and plates were incubated at indicated temperatures for 3 d. (*C*) tRNA^{Thr(CGU)}_{28,50} is efficiently modified to m³C₃₂. Bulk RNA from cells containing the integrated WT $tT(CGU)_{28,50}$ as indicated were analyzed by primer extension assay, as described in Materials and Methods, using the primer shown in *A*. The vast majority of tRNA^{Thr(CGU)}_{28,50} has m³C₃₂ based on the primer extension stop at U₃₃, compared to the amount of read-through (RT).

(D'Silva et al. 2011), and by the broad conservation of the TRM140 family and the m³C modification in eukaryotes.

One important question about S. cerevisiae Trm140 is how it recognizes its specific tRNA substrates. For enzymes such as Pus3 that modify the same residues in every tRNA, recognition typically exploits a common structural feature of tRNAs (Hur and Stroud 2007). For enzymes such as the tRNA^{His} guanylyltransferase Thg1, which only modifies tRNA^{His}, recognition of the unique GUG anticodon drives modification (Jackman and Phizicky 2006; Nakamura et al. 2013). However, several modifying enzymes recognize a specific subset of tRNAs without obvious recognition elements; examples include the m¹G₉ modification catalyzed by Trm10 for 13 of 24 species with G₉ (Swinehart et al. 2013; Swinehart and Jackman 2015) and the Cm₃₂ and Gm₃₄ modification catalyzed by Trm7 on three tRNA species (Pintard et al. 2002), as well as the $m^{3}C_{32}$ modification catalyzed by S. cerevisiae Trm140 on its six substrates (D'Silva et al. 2011; Noma et al. 2011). Indeed, simple sequence inspection suggests no common theme that would direct Trm140 modification of its three tRNA^{Thr} substrates and its three tRNA^{Ser} substrates that distinguishes these tRNAs from the 17 other S. cerevisiae tRNAs with C_{32} .

Here we define the specificity of *S. cerevisiae* Trm140 by both in vivo and in vitro approaches. We show that there

are two distinct modes of Trm140 recognition of tRNA substrates for m^3C_{32} modification. For tRNA^{Thr} species, Trm140 reads the anticodon nucleotides and the t⁶A modification, whereas for tRNA^{Ser} species, recognition is achieved through seryl-tRNA synthetase (SerRS, encoded by *SES1*) and the V-loop region, as well as i⁶A₃₇ or t⁶A₃₇.

RESULTS

An XGU anticodon and t⁶A₃₇ are necessary and sufficient for m³C modification of tRNA^{Thr} species

To begin to elucidate the specificity of Trm140, we designed a scaffold based on tRNA^{Thr(CGU)} [gene name: tT(CGU)] that would enable analysis of m³C in variants with this target scaffold independent of other tRNAs present in the cell. We altered the identity of base pairs 28:42 and 50:64 to allow us to analyze this tRNA species (tRNA^{Thr(CGU)}_{28,50}) with oligonucleotides spanning these residues (Fig. 1A). This variant was fully functional because an otherwise lethal $tT(CGU)\Delta$ strain was completely rescued upon integration of $tT(CGU)_{28,50}$, with



FIGURE 2. An XGU anticodon and t⁶A₃₇ are important for m³C modification of tRNA^{Thr(CGU)}. (*A*) G₃₅ and U₃₆ of tRNA^{Thr(CGU)} are required for m³C formation. Bulk RNA from strains containing integrated *tT* (*CGU*)_{28,50} variants with mutations as indicated were analyzed for m³C by primer extension, using a primer complementary to residues 51–37 of tRNA^{Thr(CGU)}_{28,50}. The major read-through band on the *top* of the gel corresponds to the full-length tRNA. Note that for variants with G₃₅ and U₃₆, the primer extension is slightly displaced, presumably due to a different primer extension sequence. (*B*) Summary of primer extension results of m³C ND, m³C not detected. (*C*) t⁶A₃₇ is important for m³C formation of tRNA^{Thr} species. Bulk RNA from *SUA5*⁺ and *sua5*Δ cells was analyzed by primer extension with primers as indicated, to evaluate the importance of t⁶A for m³C modification of tRNA^{Thr}(^{IGU)}, tRNA^{Thr(IGU)}.

no discernable growth defect in the range of 30°C to 37°C, compared to the corresponding strain bearing wild-type tT (*CGU*) at the same locus (Fig. 1B). The tRNA^{Thr(CGU)}_{28,50} variant was easily analyzed by primer extension independent of the wild-type tRNA^{Thr(CGU)} (Fig. 1C), and was efficiently modified to m³C; the vast majority of this tRNA has m³C₃₂, based on the prominent primer extension block at N₃₃, compared to the relatively minor read-through signal (Fig. 1C), similar to the amount of m³C modification observed for wild-type tRNA^{Thr(CGU)} (Fig. 2).

Since the tRNA^{Thr} species bearing m^3C_{32} all have similar anticodons (CGU, UGU, and IGU), we made and analyzed a set of yeast strains, each with an integrated tRNA^{Thr(CGU)}_{28,50} variant bearing a single mutation in the anticodon loop (Fig. 2A,B). Primer extension analysis showed that alteration of C₃₄ to other nucleotides resulted in retention of the major primer extension block at N₃₃, indicative of m^3C_{32} . In contrast, substitution of residue G₃₅ or U₃₆ with each of the other nucleotides resulted in almost complete loss of m^3C_{32} . These results suggest that the conserved G_{35} and U_{36} residues in the anticodons of tRNA^{Thr} species are required for m³C formation. As expected, substitution of C_{32} to U_{32} resulted in no primer extension stop.

Since U₃₆ was important for m³C modification activity, and U_{36} is always followed by t⁶A₃₇ (Machnicka et al. 2013) or, as frequently occurs in yeast and some other organisms, a cyclized derivative of t⁶A called ct⁶A (Miyauchi et al. 2013), it was possible that t^6A_{37} or ct^6A_{37} (collectively referred to as t⁶A for simplicity) also had a role in m³C formation. To examine the contribution of t⁶A to m³C modification, we analyzed m³C levels in wild-type tRNA^{Thr} species from an sua5 Δ strain, which lacks t⁶A₃₇ (El Yacoubi et al. 2009). The m³C levels in each of the three tRNA^{Thr} species from the $sua5\Delta$ strain were substantially reduced compared to those from the corresponding wild-type strain (Fig. 2C). This result suggested that t⁶A₃₇ was important, but not absolutely required, for m³C modification of the three tRNA^{Thr} species in vivo, along with the required G₃₅–U₃₆ anticodon sequence.

To probe the connection between Trm140 tRNA modification specificity and Trm140 binding, we developed a pull-down assay. In a strain in which Trm140 was overproduced with a C-terminal tandem affinity purification tag (PT), we observed highly specific copurification of tRNA substrates. Trm140 was purified using IgG Sepharose in buffer conditions predicted to maintain native protein-RNA interactions, and then bound protein was washed once and eluted with protease to release Trm140 and retained RNAs. Northern analysis of the eluted tRNAs (Fig. 3A) showed highly efficient retention of Trm140 substrate tRNAs, including tRNA^{Thr(IGU)}, tRNA^{Thr(UGU)}, tRNA^{Thr(CGU)}, relative to that in a vector control, whereas several nonsubstrate tRNAs examined did not copurify with Trm140, including tRNA^{Leu(UAA)}, tRNA^{Phe(GAA)}, and tRNA^{Trp(CCA)}. Similar copurification results were obtained upon overproduction of ORF240 (Fig. 3B), the C-terminal domain of Trm140 (comprising residues 277-628), which is necessary and sufficient for the methyltransferase activity in vivo (D'Silva et al. 2011); with either Trm140 or ORF240, we observed efficient retention of tRNA^{Thr(IGU)}, tRNA^{Ser(GCU)}, and tRNA^{Ser(UGA)/(CGA)} (which were not distinguished by the hybridization probe we used), compared to the vector control. Because ORF240 was expressed at higher levels, had slightly stronger tRNA binding signals than Trm140, and also lacked the unnecessary N-terminal domain of Trm140, we continued binding experiments with ORF240. To quantify the specificity of ORF240 tRNA binding, we analyzed biological triplicate samples for ORF240 binding of a number of different tRNAs, using two washes before the release of bound protein by proteolytic cleavage. Under these conditions, $tRNA^{Thr(CGU)}$ bound very efficiently and reproducibly, whereas four nonsubstrate tRNAs did not, including tRNA^{Phe(GAA)}, tRNA^{Lys(CUU)}, tRNA^{Met (CAU)}, and tRNA^{Ala(UGC)} (Fig. 3C). For these and subsequent experiments we calculated binding



FIGURE 3. ORF240 binding of tRNA^{Thr(CGU)} requires G_{35} and U_{36} . (A) Trm140 specifically binds tRNA^{Thr} substrates. Trm140 was purified from a WT strain expressing *TRM140-PT* (or a vector control) by pull-down using IgG Sepharose, followed by a wash step and by elution of bound Trm140 by 3C protease treatment. Then, copurifying RNAs were resolved by PAGE, transferred to nitrocellulose, and analyzed by hybridization with probes as indicated. V, vector control; T, Trm140-PT. (*B*) ORF240 binds tRNA^{Ser} substrates as efficiently as Trm140. Trm140 and ORF240 were purified from WT strains expressing *TRM140-PT* or *ORF240-PT* (or a vector control) by pull-down, and copurifying tRNAs were analyzed as in *A*. O, ORF240-PT. (*C*) ORF240 binds specifically and reproducibly to tRNA^{Thr(CGU)} and not to four nonsubstrate tRNAs. *ORF240-PT* was expressed in WT cells in biological triplicate and purified by pull-down, two wash steps, and 3C protease elution of bound ORF240, and copurifying tRNAs were analyzed as in *A*. The percentage of tRNA retained in the combined second wash and the elution step, relative to that in the crude extract was calculated for each tRNA, as indicated. CE, crude extract (0.4% loaded); W1, wash 1 (10% loaded); W2, wash 2, (10% loaded); E, elution (10% loaded). (*D*) G_{35} and U_{36} of tRNA^{Thr(CGU)} are important for binding of tRNA to ORF240. Strains containing integrated tRNA^{Thr(CGU)} variants as indicated were grown and analyzed for ORF240 tRNA binding by the pull-down assay as described in *C*. (*E*) Schematic of pull-down results in *D*.

as the percentage of tRNA in the combined second wash and the elution step, relative to that in the crude extract, because it was apparent that tRNA^{Thr(CGU)} was prominent in the second wash and the elution step, relative to the first wash, whereas the negative controls were much reduced in these fractions. These results establish that copurification of tRNA with Trm140 or ORF240 is a highly specific assay for substrate tRNA binding.

Consistent with our results from analysis of in vivo methyltransferase activity, we found that anticodon residues G_{35} and U_{36} were important for ORF240 binding as measured by this pull-down assay (Fig. 3D,E). Under these conditions, we observed reproducible copurification of wild-type tRNA^{Thr(CGU)} ($23 \pm 5\%$) and reproducible lack of copurification of tRNA^{Phe(GAA)} ($1 \pm 0.3\%$). For the tRNA^{Thr(CGU)}_{28,50} variants, substitution of G_{35} or U_{36} with each of the other three nucleotides almost completely abolished the copurification of tRNA, whereas substitution of C_{34} with other nucleotides led to high levels of variant copurification. Based on these results, we conclude that Trm140 binds tRNAs with a G_{35} – U_{36} anticodon. Since these are the same residues that are important for m³C modification, we infer that m³C modification is driven in large part by Trm140 tRNA binding. Because we found that copurification of the C_{34} variants was distinctly more efficient than the other three variants (35% versus 11%–14%), we infer that C_{34} is a modestly preferred wobble base nucleotide for ORF240 recognition. Residue 38 is likewise modestly influential for Trm140 m³C modification, since the A₃₈U or A₃₈C mutations reduced binding modestly, from 35% to 13%–15%, similar to the effects of C₃₄ mutations.

To examine the sufficiency of G₃₅-U₃₆-t⁶A₃₇ for m³C formation, we replaced the anticodon of the nonsubstrate tRNA^{Phe(GAA)} with a CGU anticodon and a G₃₇A mutation to allow for t⁶A₃₇ modification, and assayed the variant for m³C modification and tRNA binding by ORF240. As we did for tRNA^{Thr(CGU)} variants, we altered 2 bp in the stem to allow for unique detection of the tRNA^{Phe(ĜAA)} variants; in this case, we flipped the 29:41 and 50:64 pairs to make tRNA^{Phe(GAA)}29,50 (Fig. 4A). ORF240 pull-down experiments resulted in efficient copurification (29%) of the tRNA^{Phe(GAA)}29,50 [CGUA]34-37 variant, but only background copurification (1%) of tRNA^{Phe(GAA)}_{29,50} [GAAG]₃₄₋₃₇ (Fig. 4B,C). Consistent with the binding results, primer extension of RNA from cells containing the tRNA^{Phe(GAA)}29.50 [CGUA]₃₄₋₃₇ variant revealed a strong primer extension block at N₃₃, indicative of m³C modification (Fig. 4D). These binding and primer extension results of tRNA^{Phe(GAA)}29.50



FIGURE 4. An XGU anticodon and $t^{6}A_{37}$ are sufficient for ORF240 binding and for m³C modification of tRNA^{Phe}. (*A*) Schematic of tRNA^{Phe(GAA)}_{29,50} variant. The secondary structure of tRNA^{Phe} is shown, with highlighting of base pairs 29:41 and 50:64 that were flipped, and bold outline of residues N₃₄₋₃₇ that were changed from GAAG to CGUA. (*B*) A CGU anticodon and $t^{6}A_{37}$ are sufficient for binding of tRNA^{Phe} to ORF240. Strains with integrated *tF* (*GAA*)_{29,50} variants as indicated were analyzed by the ORF240 tRNA pull-down assay as described in Figure 3C. (*C*) Summary of pull-down results in *B*. (*D*) A CGU anticodon and $t^{6}A_{37}$ are sufficient for m³C modification of tRNA^{Phe}. Bulk RNA from strains without (lane 1) or with a tRNA^{Phe(GAA)}_{29,50} [CGUA]₃₄₋₃₇ variant (lane 2) was analyzed by primer extension for m³C, using a primer complementary to residues 52–36 of the variant. Lane 3, primer alone.

indicate that a CGU anticodon and A_{37} (presumably modified to t^6A) are sufficient for m^3C modification of $tRNA^{Phe}$ (GAA) and establish that this sequence is an identity element for the modification.

t⁶A₃₇ and i⁶A₃₇ are important for m³C modification of tRNA^{Ser} species

Unlike the three $tRNA^{Thr}$ Trm140 substrates, which all share the anticodon residues G₃₅ and U₃₆, the three $tRNA^{Ser}$ substrates $tRNA^{Ser(CGA)}$, $tRNA^{Ser(UGA)}$, and $tRNA^{Ser(GCU)}$ do not share any anticodon residues with one another, and therefore the major Trm140 specificity determinant for $tRNA^{Ser}$ must be elsewhere. Furthermore, although t^6A_{37} is important for Trm140 modification of $tRNA^{Thr}$, only $tRNA^{Ser(GCU)}$ has t^6A , whereas $tRNA^{Ser(CGA)}$ and $tRNA^{Ser(UGA)}$ have i^6A_{37} .

Consistent with the importance of t⁶A for m³C modification of tRNA^{Thr} species, we found that the m³C modification level of tRNA^{Ser(GCU)} was substantially lower in the *sua5* Δ strain compared to the WT strain (Fig. 5A). We also found that m³C was substantially reduced in



FIGURE 5. $t^{6}A_{37}$ and $i^{6}A_{37}$ are important for m³C modification of tRNA^{Ser} species. (*A*) $t^{6}A_{37}$ is important for m³C modification of tRNA^{Ser} (^{GCU)}. Bulk RNA from *SUA5*⁺ and *sua5* Δ cells was analyzed by primer extension with a primer annealing to residue e7–35 of tRNA^{Ser(GCU)}. (*B*) $i^{6}A_{37}$ is important for m³C modification of tRNA^{Ser(UGA)} and tRNA^{Ser(CGA)}. Bulk RNA from *MOD5*⁺ and *mod5* Δ cells was analyzed by primer extension with a primer annealing to residue e8–36 of tRNA^{Ser(CGA)}. (*C*) $i^{6}A_{37}$ is important for tRNA^{Ser(CGA)} binding to ORF240. *ORF240-PT* was expressed in *MOD5*⁺ and *mod5* Δ strains, and ORF240 tRNA binding was analyzed by the IgG Sepharose pull-down assay as described in Figure 3C. (*D*) Schematic of tRNA^{Ser} with highlighting of the V-loop containing residues N_{e1-e9} (black) and five other nucleotides (gray).

tRNA^{Ser(CGA)/(UGA)} in a *mod5* Δ strain, which lacks the i⁶A₃₇ modification (Fig. 5B; Dihanich et al. 1987), as also found for the m³C modification of tRNA^{Ser} substrates in *S. pombe* (Arimbasseri et al. 2016). Thus, it appears that both t⁶A and i⁶A contribute to efficient m³C modification.

We further showed that $i^{6}A_{37}$ was important for tRNA^{Ser} ^(CGA) binding to ORF240 (Fig. 5C). While ORF240 bound 50% of the tRNA^{Ser(CGA)} in a *MOD5*⁺ strain, it only bound 1% of this tRNA in a *mod5* Δ strain. Similarly, although tRNA^{Ser(UGA)} bound more weakly to ORF240 in a *MOD5*⁺ strain (6%), this binding was undetectable in a *mod5* Δ strain. As expected, binding of tRNA^{Ser(GCU)} was not affected in the *mod5* Δ strain, because this tRNA is not a Mod5 substrate. Because $i^{6}A_{37}$ is crucial for ORF240 binding and for m³C modification of tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)}, we infer that ORF240 binding is important for m³C formation.

Although i⁶A and t⁶A are important for recognition of tRNA^{Ser} substrates by Trm140, they could not be the sole determinants for m³C modification, since there are nine other *S. cerevisiae* tRNAs with both C_{32} and t⁶A₃₇ that lack the m³C modification, and one other tRNA with C_{32} and i⁶A that lacks m³C.

Ses1 copurifies with Trm140

One unique feature of tRNA^{Ser} species that could in principle be important for m³C modification is the distinctive long Vloop. In yeast, the tRNA^{Ser} V-loops are all 14 nt long (Fig. 5D), whereas the only other tRNAs with a long V-loop are members of the tRNA^{Leu} family, with V-loops of 13 or 15 nt. Trm140 could recognize the distinctive tRNA^{Ser} V-loop, or Trm140 might cooperate with other proteins such as seryl-tRNA synthetase, Ses1, to recognize the V-loop. Ses1 is known to recognize a V-loop of the appropriate length for its charging activity (Himeno et al. 1997).

To define proteins that interact with Trm140, we purified ORF240 under identical conditions to those we used for copurification of tRNAs, and compared the copurifying polypeptides with those of the negative control glutaminyl-tRNA synthetase, encoded by GLN4. Coomassie staining revealed three polypeptide bands that copurified with ORF240, one of which, labeled A, appeared to be shared by Gln4 (Fig. 6A). Mass spectrometry analysis showed that the major proteins in band A from Ses1 and Gln4 were the same (heat shock protein Ssa1, Ssa2, and Ssc1), and that band C corresponded to ORF240 breakdown polypeptides. However, the major polypeptides in band B were Ses1 and YNL040W, with convincing Mascot scores of 1737 and 660, respectively, and these proteins were not found at all in the corresponding Gln4 purification. Examination of a $ynl040w\Delta$ strain showed no alteration of m³C levels of tRNA^{Thr(IGU)} or tRNA^{Ser(UGA)/(CGA)}. We therefore focused on Ses1.

We found that Trm140 interacted with Ses1 in wild-type cells, because affinity purification of Trm140 with a chromosomal C-terminal MORF tag (Trm140-cMORF) resulted in



FIGURE 6. Trm140 interacts with Ses1. (A) SDS-PAGE analysis reveals three polypeptide bands that copurify with Trm140. Strains containing either PGAL-ORF240-PT or PGAL-GLN4-MORF were grown as described in Materials and Methods, ORF240 and Gln4 were affinity purified under conditions identical to those used for pull-down assays, and proteins were analyzed by SDS-PAGE and Coomassie staining. Three distinct copurifying bands that were found in the ORF240 preparation (lane 3) are labeled A-C. (B) Chromosomally expressed Ses1-Myc and Trm140-cMORF interact. Trm140 was affinity purified from crude extracts of the indicated strains, using IgG Sepharose and 3C protease cleavage. Crude extract (input) was subjected to immunoblot analysis with anti-HA and anti-(c-myc) antibody, and IgG-purified protein (immunoprecipitate, IP) was analyzed by immunoblot with anti-(c-myc) antibody. (C) Overproduction of ORF240-PT results in increased copurification of Ses1. Trm140 was purified from a chromosomally tagged Trm140-cMORF strain, ORF240 was purified from a strain overexpressing ORF240-PT, and the amount of copurifying Ses1 was compared by immunoblot, as described in B.

copurification of chromosomally tagged Ses1-myc (Fig. 6B, cf. lanes 3 and 5), but no obvious copurification of the control Vas1-Myc (valyl-tRNA synthetase) (Fig. 6B, lanes 4,6). Moreover, overproduction of ORF240-PT under P_{GAL} control resulted in copurification of substantially increased amounts of Ses1-myc (Fig. 6C, lanes 4,5). This interaction of Trm140 with Ses1 suggested the possibility that Ses1 might have a role in the m³C modification reaction.

Ses1 stimulates m³C formation of tRNA^{Ser} species

To determine if Ses1 had a role in m^3C modification, we examined the methyltransferase activity of Trm140 in vitro. We expressed and purified His₆-ORF240 from *Escherichia coli* and assayed its activity with tRNA purified from a *trm140* Δ strain. After incubation of ORF240 with *S*-adenosylmethionine (SAM) and tRNA, we analyzed m^3C modification by primer extension in the presence of ddTTP, and calculated

TABLE 1. Summary of the efficiency of ORF240 m ³ C methyltransferase activity on tRNA ^{Thr} and tRNA ^{Ser} substrates							
tRNA ^a	ORF240 _{1/2} (µM)	ORF240 _{1/2} (μM) with 1.5 μM Ses1					
tRNA ^{Thr(IGU)}	0.02	0.02					
tRNA ^{Thr(UGU)}	0.02	_					
tRNA ^{Thr(CGU)}	0.02	_					
tRNA ^{Ser(GCU)}	0.05	0.02					
tRNA ^{Ser(CGA)}	0.3	0.02					
tRNA ^{Ser(UGA)}	~15 ^b	0.3					
$tRNA^{Tyr(GUA)}$	>30 ^b	>30 ^b					

^bEstimated from activity at 2.5 μ M ORF240.

the efficiency of m³C modification based on the intensities of the primer extension blocks at U₃₃, due to m³C₃₂, and at A₃₁, due to read-through and termination by ddTTP incorporation. Using this assay, we found that the three tRNA^{Thr} species were equally efficiently modified by ORF240 (Table 1; Fig. 7A,B), in each case requiring ~0.02 μ M ORF240 for one-half-maximal modification (ORF240_{1/2}). In contrast, ORF240 was very inefficient at m³C modification of tRNA^{Ser(UGA)} and tRNA^{Ser(CGA)}, with ORF240_{1/2} values of ~15 μ M and ~0.3 μ M, respectively, while the ORF240_{1/2} value was ~0.05 μ M for tRNA^{Ser(GCU)}. As anticipated, no m³C was detected upon ORF240 assay of tRNA^{Tyr(GUA)}, which normally bears an unmodified C₃₂ (Table 1).

Consistent with an important biological role for the interaction of Trm140 with Ses1, we found that purified Ses1 stimulated the Trm140 m³C modification activity on tRNA^{Ser} species in vitro. Using Ses1 purified from a *trm140* strain, to avoid Trm140 contamination, we found that 1.5 μ M Ses1 reduced the ORF240_{1/2} of tRNA^{Ser(CGA)} from ~0.3 μ M to ~0.02 μ M, of tRNA^{Ser(UGA)} from ~15 μ M to ~0.3 μ M, and of tRNA^{Ser(GCU)} from 0.05 μ M to 0.02 μ M, but had little or no effect on tRNA^{Thr(IGU)} or tRNA^{Tyr(GUA)} (Table 1; Fig. 8A,B).

Consistent with these in vitro results, we observed Ses1 stimulation of m^3C modification in vivo. To address this question, we assayed m^3C modification after overproduction of Ses1-MORF in a *mod5* Δ strain, in which m^3C_{32} modification of tRNA^{Ser(CGA)/(UGA)} was reduced due to lack of i⁶A (Fig. 5B). We found that overproduction of Ses1 resulted in a substantial increase in m^3C levels of tRNA^{Ser(CGA)/(UGA)} relative to that in the vector control, from 2% to 24% (Fig. 9A). Overproduction of ORF240 also improved the m^3C modification, consistent with the fact that i⁶A was important for ORF240 binding. As expected, the m^3C levels of tRNA^{Thr} (^{IGU)}, which has t⁶A and not i⁶A, were not affected in the *mod5* Δ strain or by overproduction of oRF240.

To determine whether the important region for m^3C modification of tRNA^{Ser} species was the V-loop, we tested the modification of a chimeric tRNA^{Leu} species with a V-loop based on tRNA^{Ser}. We constructed a variant with the body sequence of tRNA^{Leu(UAA)}, the anticodon UGA, and A₃₇, called variant M1 (Fig. 9B). This M1 variant was not a substrate for m^3C modification (Fig. 9C, lane 2). However, the variant M2, which differs from M1 due to replacement of the V-loop with that of tRNA^{Ser(GCU)}, was significantly modified to m^3C_{32} (Fig. 9C, lane 5). This result shows that the tRNA^{Ser} V-loop is sufficient to confer m^3C_{32} modification of the M1 variant in the context of this tRNA species.

DISCUSSION

We have provided evidence here that *S. cerevisiae* Trm140 has two strikingly different recognition modes for tRNA m³C modification. Trm140 explicitly recognizes the XGU anticodon and t⁶A₃₇ of tRNA^{Thr} species as an identity element for m³C modification in vivo. Thus, substitution of either G₃₅ or U₃₆ of tRNA^{Thr(CGU)} with any other residue resulted in the complete absence of m³C modification, and removal of t⁶A substantially reduced m³C modification, whereas introduction of a CGU anticodon and A₃₇ to tRNA^{Phe} resulted in efficient m³C modification in vivo. Consistent with these



FIGURE 7. ORF240 catalyzes efficient m³C modification of tRNA^{Thr(IGU)} but inefficient modification of tRNA^{Ser(CGA)}. (*A*) Titration of ORF240 m³C methyltransferase activity on tRNA^{Thr(IGU)} and tRNA^{Ser(CGA)}. Of note, 0.35 pmol of tRNA^{Thr(IGU)} or tRNA^{Ser(CGA)} purified from a *trm140*Δ strain was incubated with serial fivefold dilutions of ORF240 (2.5, 0.5, 0.1, 0.02, 0.004 μ M) purified from *E. coli* or with buffer (–) in the presence of SAM at 30°C for 1 h, and tRNA was analyzed for m³C by primer extension in the presence of ddTTP, as described in Materials and Methods. (*B*) Plot of m³C modification as a function of the concentration of ORF240 in *A*.



FIGURE 8. Ses1 stimulates ORF240 m³C modification of tRNA^{Ser(UGA)} and tRNA^{Ser(CGA)}. (*A*) Effect of Ses1 on the titration of ORF240 m³C methyltransferase activity on tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)}. Of note, 0.35 pmol of tRNA^{Ser(UGA)} and tRNA^{Ser(CGA)} purified from a *trm140*Δ strain was assayed for m³C formation by ORF240 in the presence or absence of 1.5 μ M Ses1 purified from a *trm140*Δ strain, as described in Figure 7A. (*B*) Plot of m³C modification as a function of the concentration of ORF240 in *A*.

results, ORF240 expressed and purified from *E. coli* efficiently catalyzed modification of all three tRNA^{Thr} species, but not tRNA^{Tyr}.

In contrast, the CGA, UGA, and GCU anticodons of the three tRNA^{Ser} species that are modified with $m^{3}C_{32}$ do not have a common feature, and Trm140 recognition of these species is instead propelled by interaction with Ses1 and the tRNA^{Ser} V-loop, as well as by $i^{6}A_{37}$ of tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)}, and $t^{6}A_{37}$ of tRNA^{Ser(GCU)}. Thus, purified Ses1 stimulated the efficiency of ORF240 $m^{3}C$ modification of tRNA^{Ser(UGA)}, decreasing ORF240_{1/2} by 20-fold, to a value comparable to that of tRNA^{Thr} substrates. Similarly, Ses1 stimulated the efficiency of ORF240 $m^{3}C$ modification of tRNA^{Ser(UGA)} by ~50-fold. Furthermore, this Ses1 stimulation of $m^{3}C$ modification was also observed in vivo, since Ses1 overproduction significantly increased $m^{3}C$ modification of tRNA^{Ser(CGA)/(UGA)} in a strain lacking $i^{6}A$.

Our results suggest that m³C modification activity is driven in part by binding. We showed that all six known Trm140 substrate tRNAs copurified with Trm140 or ORF240, whereas each of six tested nonsubstrate tRNAs did not copurify. We also showed that ORF240 binding of tRNA^{Thr} anticodon loop variants tracked perfectly with m³C modification, since

all six possible variants with mutations in G₃₅ or U₃₆ lacked modification and also did not bind, whereas each of the three variants with mutations in C34 were modified and bound efficiently, although not as efficiently as with C34. Furthermore, ORF240 bound tRNA^{Phe} efficiently only when its anticodon was altered to CGU-A₃₇, correlated with m³C modification, and i⁶A₃₇ was important for binding of tRNA^{Ser(CGA)} to ORF240 as well as for m³C modification. These results suggest a modular binding mechanism to explain substrate specificity, in which contributions are made by G₃₅, U₃₆, i⁶A₃₇, or t⁶A₃₇, and the V-loop, as well as C₃₄. C₃₄ is favored over other N34 residues based on preferential binding of $tRNA^{Thr}\ C_{34}$ variants and preferential binding of tRNA^{Ser(CGA)} compared to tRNA^{Ser(UGA)} since these two tRNAs are identical other than U_{34} and the $N_{28}\text{-}N_{42}$ pair. This preferential binding of $tRNA^{Ser(\mathrm{CGA})}$ relative to that of tRNA^{Ser(UGA)} is also consistent with the preferential ORF240 modification activity of tRNA^{Ser(CGA)} compared to tRNA^{Ser(UGA)}

Proteins like Trm140 that bind nucleic acids by two very different modes are rare. Notable examples include TFIIIA, which recognizes 5S promoter DNA and 5S RNA using distinctive zinc fingers (Nolte et al. 1998; Lu et al. 2003; Hall 2005), and phage λ integrase protein, which recognizes two different DNA sequences with different domains (Moitoso de Vargas et al. 1988). It is intriguing that bovine mitochondrial Ses1 recognizes tRNA^{Ser} substrates with and without a D-stem–loop by different mechanisms, but involving the same region of the T-loop (Shimada et al. 2001); the different modes of Trm140 recognition of tRNA^{Thr} compared to tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)} also appear to involve common elements including C₃₄ and i⁶A₃₇ or t⁶A₃₇, as well as the specific involvement of Ses1 for tRNA^{Ser} and G₃₅–U₃₆ for tRNA^{Thr}.

The observation that i⁶A and t⁶A are important for m³C modification is a clear demonstration of ordered modification circuitry in the anticodon loops of tRNA^{Thr} and tRNA^{Ser}, in which either A₃₇ modification drives m³C formation. Maraia and coworkers recently observed that i⁶A modification was important for m³C₃₂ modification in tRNA^{Ser} species of S. pombe and speculated that t⁶A modification would be important for m³C₃₂ modification of tRNA^{Thr} and tRNA^{Ser} substrates with U_{36} (Arimbasseri et al. 2016). Because we observed that i⁶A is important for both tRNA binding and m³C modification, this suggests that tRNA binding efficiency is at least partially responsible for the observed ordering of these two modifications. It remains to be determined how both t⁶A and i⁶A drive the same m³C modification reaction, and in particular if t⁶A₃₇ stimulates m³C modification due to increased Trm140 tRNA binding. Our preliminary attempts to express ORF240 in an sua5 mutant strain have been unsuccessful.

The ordered modification circuitry described above for m³C modification of tRNA^{Ser} and tRNA^{Thr} is reminiscent of the conserved ordered modification circuitry found in



FIGURE 9. Ses1 stimulates m³C modification of tRNA^{Ser(CGA)} and tRNA^{Ser(UGA)} in vivo and the unique tRNA^{Ser} V-loop that Ses1 recognizes is important for m³C modification. (*A*) Ses1 stimulates m³C formation in vivo. Bulk RNA from *mod5* Δ cells expressing *SES1*, *ORF240*, vector, or *MOD5* as indicated was analyzed for m³C of tRNA^{Ser(CGA)/(UGA)} or tRNA^{Thr(IGU)} by primer extension in the presence of ddTTP, as described in Materials and Methods. (*B*) Schematic of tRNA^{Leu(UAA)} M1 and M2 variants. The secondary structure of tRNA^{Leu(UAA)} M1 is shown, with anticodon loop mutations as indicated (circled). Nucleotides in the V-loop that were changed to the V-loop of tRNA^{Ser(GCU)} to make the tRNA^{Leu(UAA)} M2 variant are boxed. (*C*) The variable loop of tRNA^{Ser(GCU)} is sufficient to confer m³C modification in vivo of tRNA^{Leu}(^{UAA)} with G₃₅ and A₃₇ mutations. Variants described in *B* were integrated into a *trm732* Δ strain, to eliminate the possibility of 2'-O-methylation at C₃₂ (Guy et al. 2012), and bulk RNA from strains containing either variants M1 or M2 was analyzed for m³C by primer extension, using ddTTP and primers extending from residue e8 to 36 of M1 and from residue 47 to 36 of M2.

the anticodon loop of tRNA^{Phe}. We previously showed that complete modification of the anticodon loop of *S. cerevisiae* tRNA^{Phe} required 2'-O-methylation of C_{32} and G_{34} to drive efficient formation of wybutosine at m¹G₃₇ (Guy et al. 2012), and that this circuitry for tRNA^{Phe} anticodon loop modification was conserved in *S. pombe* and human lymphoblastoid cell lines (Guy and Phizicky 2015; Guy et al. 2015). The similar conservation of modification order for i⁶A/t⁶A and m³C in the anticodon loops of tRNA^{Thr} and tRNA^{Ser} species in *S. cerevisiae* and *S. pombe* suggests that this ordered modification circuitry will be preserved in other eukaryotes, perhaps by conserved mechanisms, and suggests the existence of other circuits for anticodon loop modifications.

The stimulation by Ses1 of Trm140 m³C modification activity that we observe in vitro and in vivo could occur in two ways. One possibility is that Trm140, Ses1, and tRNA form three binary interactions, which might stabilize weak enzyme–substrate binding. We have shown that Ses1-myc copurified with Trm140-cMORF, although it remains to be determined whether the interaction is tRNA mediated. Alternatively, it is possible that binding of tRNA^{Ser} to Ses1 rearranges the local conformation of the anticodon loop to facilitate Trm140 recognition of C₃₂, although the cocrystal structures of both *Thermus thermophilus* SerRS-tRNA^{Ser} and human SerRS-tRNA^{Sec} lack any direct interaction between the synthetases and the anticodon loop (Biou et al. 1994; Wang et al. 2015). It is known that *S. cerevisiae* Ses1 recognizes the V-loop of tRNA^{Ser} for its synthetase activity (Himeno et al. 1997), providing a probable explanation for the V-loop dependence of $m^{3}C$ modification, but not casting light on its mechanism of $m^{3}C$ stimulation.

The two modes of tRNA substrate recognition for S. cerevisiae Trm140 seems likely to be found widely in the Saccharomycotina and Pezizomycotina subdivisions of the phylum Ascomycota, and to a more limited extent in Basidiomycota, based on the occurrence of a single highly similar TRM140 homolog in a large fraction of these organisms that we examined (Candida albicans, Candida tropicalis, Yarrowia lipolytica, Saccharomyces castellii, Debaryomyces hansenii, Candida glabrata, Saccharomyces mikatae, Saccharomyces paradoxus, Saccharomyces bayanus, Kluyveromyces lactis, Ashbya gossypii, Saccharomyces kluyveri, Kluyveromyces waltii, Aspergillus nidulans, Aspergillus oryzae, Neurospora crassa, Coccidioides posadasii, Coccidioides immitis, Coprinopsis cinerea, Phanerochaete chrysosporium, Uncinocarpus reesii. Chaetomium globosum, Fusarium verticil-

lioides, Botrytis cinerea). However, split substrate recognition by Trm140 and related proteins is also likely widely found since S. pombe was recently shown to have separate trm140+ and trm141+ (METTL6) homologs dedicated to tRNA^{Thr} and to tRNA^{Ser} substrates, respectively, and multiple homologs appear to be the rule rather than the exception in metazoans, plants, and other groups of fungi (Arimbasseri et al. 2016). Thus, a large number of eukaryotes, including vertebrates, have two or three TRM140 family members, drawn from the phylogenetic clades of TRM140, METTL6, METTL2, and METTL8 homologs, which might be used for modification of specific tRNA species with m³C₃₂ or with m³C in the V-loop (Arimbasseri et al. 2016). In view of our findings, we speculate that tRNA^{Ser} m³C modification activity in other organisms might also be stimulated by SerRS. In support of this, we note that the human SerRS has the same Vloop recognition element as yeast Ses1 (Achsel and Gross 1993). Alternatively, it is possible that the different homologs have evolved separate tRNA recognition elements in S. pombe and other organisms. The recent finding that the METTL6 homolog TbMTase37 of T. brucei is important for ribosome stability and cytokinesis emphasizes the importance of this family of proteins, although the proximate cause is not yet known (Fleming et al. 2016).

The Ses1 requirement for efficient Trm140 m³C modification of tRNA^{Ser} species adds to a small subset of the two-subunit modification enzymes (Guy and Phizicky 2014) in which one interacting partner seemingly directs the enzyme to different residues or substrates, including Trm7/Trm732 for Nm₃₂ formation, Trm7/Trm734 for Nm₃₄ formation (Guy et al. 2012; Guy and Phizicky 2015), and Kre33/Tan1 for ac⁴C₁₂ formation (Johansson and Bystrom 2004; Sharma et al. 2015). The finding of Ses1 as an interacting partner for Trm140 m³C modification is also another example of the remarkable range of different noncanonical functions of tRNA synthetases (Wakasugi and Schimmel 1999; Guo et al. 2010; Smirnova et al. 2012; Yao and Fox 2013), at least some of which exert these roles through RNA interactions (Herbert et al. 1988; Sampath et al. 2004; Sarkar et al. 2012). It remains to be determined precisely how Ses1 recognizes Trm140 to stimulate m³C modification activity of tRNA^{Ser}, and the connection between tRNA^{Ser} charging and modification.

MATERIALS AND METHODS

Yeast strains

Strains (listed in Table 2) used for genetic tests and/or analysis of tRNA were derivatives of strain BY4741 or BY4742, strains used for immunoblotting analysis were derivatives of BCY123, and strains used for pull-down experiments and protein purification were derivatives of YLH126.

TRM140 was deleted by PCR amplification of the *trm140* Δ ::*ble*^{*R*} cassette from ySD179 using primers containing sequences 5' and 3' of *TRM140* (TRM140 – 409 and TRM140 + 307), followed by transformation, selection on YPD media containing 8 mg/L Bleocin and verification by PCR using appropriate primers. *MOD5* was deleted in a similar fashion.

The $tT(CGU)\Delta[CEN URA3 tT(CGU)]$ strain was constructed by transformation of BY4741 with the [CEN URA3 tT(CGU)] plasmid containing the tT(CGU) gene with its own flanking sequence, followed by PCR amplification of the ble^R marker and linear transformation to delete the tT(CGU) gene.

Strains with the chromosomal cMORF tag (His₆-HA-3C site-ZZ domain of protein A) were generated by PCR amplification of

a gene-specific product from a cMORF::URA3 cassette of pAVA0258, followed by linear transformation and selection (Gelperin et al. 2005; Guy et al. 2012). C-terminal myc-tagged strains were generated in a similar fashion from the pYM46 1myc-7His:: Kan^{R} cassette (Janke et al. 2004).

Plasmids

Plasmids used in this study are listed in Table 3. Plasmids expressing tRNAs were constructed by ligation-independent cloning (LIC) of a tRNA with its own flanking sequence into the [2μ *LEU2*] LIC vector pAVA577. LIC was also used to build the [*CEN URA3 MOD5*] plasmid. Integration vectors for tRNA variants were made by insertion of a BgIII, XhoI fragment encoding the tRNA variant into plasmid pAB230-1, as previously described (Guy et al. 2014). ORF240 was cloned by LIC into a [2μ *URA3* $P_{GAL1,10}$] expression vector, in which ORF240 is expressed under P_{GAL1} control with a C-terminal PT tag (as ORF240-3C site-HA epitope-His6-ZZ domain of protein A) essentially as previously described (Quartley et al. 2009).

Expression and affinity purification of Ses1-MORF from yeast

To purify Ses1 from yeast without interacting Trm140, strain YLH974-1 (*trm140* Δ) was transformed with a [2µ URA3 P_{GAL}-SES1-MORF] plasmid encoding a SES1-MORF fusion protein (Ses1-His₆-HA-3C site-ZZ domain of protein A), and the resulting strain was grown in selective media containing raffinose and induced for 6 h by addition of one-half volume of 3× YP media containing 6% galactose and 6% raffinose. Then Ses1-MORF was affinity purified using IgG Sepharose chromatography, followed by Ses1 elution with GST-3C protease, removal of the protease with glutathione Sepharose resin, and dialysis into buffer containing 50% glycerol, 20 mM Tris–Cl pH 7.5, 150 mM NaCl, 1 mM MgCl₂, and 1 mM DTT, as previously described (Quartley et al. 2009).

THELE 2. Statilis used in ans study				
Strain	Genotype	Source		
BY4741	MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0	Open Biosystems		
BY4742	MAT α his3 Δ 1 leu2 Δ 0 lys2 Δ 0 ura3 Δ 0	Open Biosystems		
BCY123	MATa pep4Δ::HIS3 prbΔ::LEU2 bar1Δ::HISG lys2Δ::GAL1/10-GALΔ4 can1 ade2 ura3 leu2-3, 112	Macbeth et al. (2005)		
YLH562-1	BY4741 $tT(CGU)\Delta$:: ble^{R} [CEN URA $tT(CGU)K$]	This study		
T14	cyc1-1019 cyc7-67 ura3-52 leu2-3, 112 cyh2	Na et al. (1992)		
YJN64	cyc1-1019 cyc7-67 ura3-52 leu2-3, 112 cyh2, sua5::LEU2	Na et al. (1992)		
YLH126	leu2Δ trp1Δ ura3Δ prb1-1122 pep4-1 his3Δ::P _{GAL10} -GAL4	Erin O'Shea		
ySD844	BY4741 $mod5\Delta$::kan ^R	This study		
ySD356	BCY123 TRM140-cMORF-URA3	This study		
YLH1302-1	BCY123 SES1-1Myc-7His::kan ^R	This study		
YLH1305-1	BCY123 VAS1-1Myc-7His::kan ^R	This study		
YLH1307-1	BCY123 TRM140-cMORF::URA3 SES1-1Myc-7His::kan ^R	This study		
YLH1310-1	BCY123 TRM140-cMORF::URA3 VAS1-1Myc-7His::kan ^R	This study		
yMG814-1	BY4741 $trm732\Delta$::ble ^R	Guy et al. (2012)		
ySD179	BY4742 $trm140::ble^{R}$	D'Silva et al. (2011)		
YLH974-1	YLH126 trm140::ble ^R	This study		

TABLE 2. Strains used in this study

TABLE 3. Plasmids used in this study					
Plasmid	Parent	Description	Source		
BG2663		2μ URA3 P _{GAL}	Quartley et al. (2009)		
pSD142	BG2663	2μ URA3 P _{GAL} -TRM140-PT	D'Silva et al. (2011)		
pSD252	BG2663	2μ URA3 P _{GAL} -ORF240-PT	This study		
pAB230-1	pJW132	ade2::5'tH(GUG)G2::Fluc	Guy et al. (2014)		
pELH248-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU)	This study		
pELH249-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U	This study		
pELH307-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U C32U	This study		
pELH308-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U C34A	This study		
pELH309-4	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U C34U	This study		
pELH310-4	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U C34G	This study		
pELH311-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U G35A	This study		
pELH312-2	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U G35U	This study		
pELH313-4	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U G35C	This study		
pELH314-2	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U U36A	This study		
pELH315-2	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U U36C	This study		
pELH316-5	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U U36G	This study		
pELH317-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U A38U	This study		
pELH318-1	pAB230-1	ade2::5'tH(GUG)G2::tT(CGU) C28G–G42C U50A–A64U A38C	This study		
pELH328-2	pAB230-1	ade2::5'tH(GUG)G2::tF(GAA) A29U–U41A U50A–A64U	This study		
pELH329-2	pAB230-1	ade2::5'tH(GUG)G2::tF(GAA) A29U–U41A U50A–A64U CGUA[34–37]	This study		
pJE832A		His ₆ -GLN4-MORF	Grant et al. (2012)		
pYM46		1Myc-7His::kan ^R	Janke et al. (2004)		
pAVA577		2µ LEU2 LIC vector	Alexandrov et al. (2006)		
pJW038	pAVA577	$2\mu LEU2 tS(CGA)$	Whipple et al. (2011)		
pEKD9094	pAVA577	2μ LEU2 tT(CGU)	Han et al. (2015)		
pJW043	pAVA577	$2\mu LEU2 tS(UGA)$	Han et al. (2015)		
pELH106-1	pAVA577	2μ <i>LEU2 tT(UGU)</i>	Han et al. (2015)		
pELH419-1	pAVA577	2μ LEU2 tS(GCU)F	This study		
pAVA579		CEN URA3 LIC vector	Quartley et al. (2009)		
pELN010	pAVA579	CEN URA3 MOD5	This study		
pAVA0258		His ₆ -HA-3C-protein A::URA3 cassette	Gelperin et al. (2005)		
pJE1256A		P _{GAL} -SES1-MORF	Gelperin et al. (2005)		
pAVA421		pT7-His ₆ -3C site-ORF LIC vector	Quartley et al. (2009)		
pSD248	pAVA421	His ₆ -3C-ATG-ORF240	D'Silva et al. (2011)		

Growth and affinity purification of His6-ORF240 from *E. coli*

The *E. coli* expression plasmid pSD248, which expresses the entire C-terminal domain of *TRM140* (residues 277–628, called ORF240) as a His6-3C-ORF240 fusion, was transformed into pLys(S)BL21 (DE3) cells. Transformants were grown, induced, and harvested, and then tagged protein was purified using immobilized metal ion affinity chromatography (IMAC), followed by imidazole elution, cleavage of the affinity tag with protease 3C, removal of contaminants by passage through the same IMAC resin, and dialysis into buffer containing 50% glycerol, 20 mM Tris–Cl, pH 7.5, 200 mM NaCl, and 1 mM DTT, essentially as previously described (D'Silva et al. 2011).

Extraction of bulk RNA from yeast and purification of tRNA

Strains were grown to an OD_{600} 1–2, and bulk RNA was extracted from ~300 OD pellets (for tRNA purification) or from ~3 OD pellets (for primer extension analysis) using hot phenol. tRNA was purified from ~1.25 mg bulk RNA using 5'-biotinylated oligonucleotides (Integrated DNA Technologies), as previously described (Jackman et al. 2003).

Primer extension assays

Primers were 5' end labeled and purified as previously described (D'Silva et al. 2011). In a 5 μ L annealing reaction, 0.25–1 pmol of labeled primers were annealed to 0.4–3 μ g of bulk RNA or ~3 ng of purified tRNA by incubation for 3 min at 95°C followed by slow cooling and incubation for 30 min at 50°C–55°C. The annealing product was then extended using 64 U Superscript III (Invitrogen) in a 10 μ L reaction containing 1× First Strand buffer, 1 mM of each dNTP, and 10 mM MgCl₂ at 50°C–55°C for 1 h. For reactions containing ddTTP, dTTP was replaced by 2 mM ddTTP, and other dNTPs were reduced to 0.5 mM. Reactions were stopped by addition of 2× RNA loading dye containing 98% formamide, 10 mM EDTA, 1 mg/mL bromophenol blue, and 1 mg/mL xylene cyanol, resolved on a 7M urea–15% polyacrylamide gel, and the dried gel was imaged on a Typhoon phosphorimager and quantified as previously described (Jackman et al. 2003).

ORF240 and Trm140 pull-down assays of tRNA binding

Strains expressing P_{GAL} -ORF240-PT or P_{GAL} -TRM140-PT plasmid were grown in selective media containing raffinose to OD₆₀₀ ~0.75 and induced for 6 h with one-half volume 3× YP media containing 6% galactose and 6% raffinose. Then tagged proteins were affinity purified from 320–360 OD pellets using IgG Sepharose, followed by one or two washes with 1 mL buffer and 3 min of mixing, and then overnight incubation with GST-3C protease to release bound protein and copurifying tRNAs. Then RNA was purified from each fraction, resolved by PAGE, and tRNAs were analyzed by hybridization, as previously described (Alexandrov et al. 2006).

Mass spectrometry

For mass spectrometry analysis of ORF240 binding proteins, ORF240-PT purification was done as for a pull-down assay, proteins were analyzed by SDS-PAGE, and copurifying polypeptides were analyzed by the Mass Spectrometry Resource Center of the University of Rochester Medical Center.

Immunoblotting analysis

Yeast strains with C-terminal chromosomal tags (cMORF or myc) were grown in YPD to OD_{600} 1–2.5 and crude extracts were made from 500–600 OD-mL pellets, followed by IgG Sepharose affinity purification and elution of bound protein with GST-3C protease. Then samples were subject to SDS-PAGE, transferred to nitrocellulose membrane (Bio-Rad), and probed with appropriate antibodies: mouse monoclonal anti-[c-myc] (Roche), followed by goat anti-mouse IgG-HRP (Bio-Rad); or rat anti-HA (Roche), followed by goat anti-rat IgG-HRP (Bio-Rad). Strains containing a P_{GAL} -ORF240-PT plasmid were grown as described in pull-down experiment.

Assay of m³C methyltransferase activity in vitro

Reaction mixtures (20 µL) contained 60–67.5 mM NaCl, 50 mM Hepes, pH 7.5, 3 mM MgCl₂, 55–60 µg/mL BSA, 50 µM EDTA, 2.5–3.5 mM Tris–Cl pH 7.5, 2.5–5% glycerol, 0.5 mM SAM, 50 µg/mL Poly(A), 10 ng of purified and refolded tRNA from a *trm140*Δ strain, ORF240 purified from *E. coli*, and where indicated, Ses1 purified from a *trm140*Δ strain or compensating buffer. Reactions were incubated at 30°C for 1 h, stopped by phenol extraction, and then tRNA was precipitated with ethanol, resuspended in water, and subjected to primer extension analysis to analyze m^3C_{32} .

ACKNOWLEDGMENTS

We thank E. O'Shea and M. Hampsey for strains, S. Ghaemmaghami and K. Welle of the Mass Spectrometry Resource Center of the University of Rochester Medical Center, and E. Grayhack for valuable discussions and comments during the course of this work. This research was supported by National Institutes of Health grant GM052347 to E.M.P.

Received October 20, 2016; accepted December 12, 2016.

REFERENCES

- Achsel T, Gross HJ. 1993. Identity determinants of human tRNA^{Ser}: sequence elements necessary for servlation and maturation of a tRNA with a long extra arm. *EMBO J* **12**: 3333–3338.
- Agris PF, Vendeix FA, Graham WD. 2007. tRNA's wobble decoding of the genome: 40 years of modification. *J Mol Biol* **366**: 1–13.
- Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, Phizicky EM. 2006. Rapid tRNA decay can result from lack of nonessential modifications. *Mol Cell* 21: 87–96.
- Arimbasseri AG, Iben J, Wei FY, Rijal K, Tomizawa K, Hafner M, Maraia RJ. 2016. Evolving specificity of tRNA 3-methyl-cytidine-32 (m³C32) modification: a subset of tRNAs^{Ser} requires N⁶-isopentenylation of A37. RNA 22: 1400–1410.
- Auffinger P, Westhof E. 1999. Singly and bifurcated hydrogen-bonded base-pairs in tRNA anticodon hairpins and ribozymes. J Mol Biol 292: 467–483.
- Biou V, Yaremchuk A, Tukalo M, Cusack S. 1994. The 2.9 A crystal structure of *T. thermophilus* seryl-tRNA synthetase complexed with tRNA^{Ser}. *Science* **263**: 1404–1410.
- Bjork GR, Jacobsson K, Nilsson K, Johansson MJ, Bystrom AS, Persson OP. 2001. A primordial tRNA modification required for the evolution of life? *EMBO J* **20:** 231–239.
- Bjork GR, Huang B, Persson OP, Bystrom AS. 2007. A conserved modified wobble nucleoside (mcm⁵s²U) in lysyl-tRNA is required for viability in yeast. *RNA* 13: 1245–1255.
- Chen C, Huang B, Eliasson M, Ryden P, Bystrom AS. 2011. Elongator complex influences telomeric gene silencing and DNA damage response by its role in wobble uridine tRNA modification. *PLoS Genet* **7**: e1002258.
- Dihanich ME, Najarian D, Clark R, Gillman EC, Martin NC, Hopper AK. 1987. Isolation and characterization of *MOD5*, a gene required for isopentenylation of cytoplasmic and mitochondrial tRNAs of *Saccharomyces cerevisiae*. *Mol Cell Biol* **7**: 177–184.
- D'Silva S, Haider SJ, Phizicky EM. 2011. A domain of the actin binding protein Abp140 is the yeast methyltransferase responsible for 3-methylcytidine modification in the tRNA anti-codon loop. *RNA* **17:** 1100–1110.
- El Yacoubi B, Lyons B, Cruz Y, Reddy R, Nordin B, Agnelli F, Williamson JR, Schimmel P, Swairjo MA, de Crecy-Lagard V. 2009. The universal YrdC/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA. *Nucleic Acids Res* 37: 2894–2909.
- El Yacoubi B, Hatin I, Deutsch C, Kahveci T, Rousset JP, Iwata-Reuyl D, Murzin AG, de Crécy-Lagard V. 2011. A role for the universal Kae1/ Qri7/YgjD (COG0533) family in tRNA modification. *EMBO J* 30: 882–893.
- Esberg A, Huang B, Johansson MJ, Bystrom AS. 2006. Elevated levels of two tRNA species bypass the requirement for elongator complex in transcription and exocytosis. *Mol Cell* **24**: 139–148.
- Fleming IM, Paris Z, Gaston KW, Balakrishnan R, Fredrick K, Rubio MA, Alfonzo JD. 2016. A tRNA methyltransferase paralog is important for ribosome stability and cell division in *Trypanosoma brucei*. Sci Rep 6: 21438.
- Gelperin DM, White MA, Wilkinson ML, Kon Y, Kung LA, Wise KJ, Lopez-Hoyo N, Jiang L, Piccirillo S, Yu H, et al. 2005. Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. *Genes Dev* **19:** 2816–2826.
- Gerber AP, Keller W. 1999. An adenosine deaminase that generates inosine at the wobble position of tRNAs. *Science* **286**: 1146–1149.
- Grant TD, Snell EH, Luft JR, Quartley E, Corretore S, Wolfley JR, Snell ME, Hadd A, Perona JJ, Phizicky EM, et al. 2012. Structural conservation of an ancient tRNA sensor in eukaryotic glutaminyltRNA synthetase. *Nucleic Acids Res* **40**: 3723–3731.
- Guo M, Yang XL, Schimmel P. 2010. New functions of aminoacyl-tRNA synthetases beyond translation. Nat Rev Mol Cell Biol 11: 668–674.
- Guy MP, Phizicky EM. 2014. Two-subunit enzymes involved in eukaryotic post-transcriptional tRNA modification. *RNA Biol* 11: 1608–1618.

- Guy MP, Phizicky EM. 2015. Conservation of an intricate circuit for crucial modifications of the tRNA^{Phe} anticodon loop in eukaryotes. *RNA* **21:** 61–74.
- Guy MP, Podyma BM, Preston MA, Shaheen HH, Krivos KL, Limbach PA, Hopper AK, Phizicky EM. 2012. Yeast Trm7 interacts with distinct proteins for critical modifications of the tRNA^{Phe} anticodon loop. *RNA* 18: 1921–1933.
- Guy MP, Young DL, Payea MJ, Zhang X, Kon Y, Dean KM, Grayhack EJ, Mathews DH, Fields S, Phizicky EM. 2014. Identification of the determinants of tRNA function and susceptibility to rapid tRNA decay by high-throughput in vivo analysis. *Genes Dev* **28**: 1721–1732.
- Guy MP, Shaw M, Weiner CL, Hobson L, Stark Z, Rose K, Kalscheuer VM, Gecz J, Phizicky EM. 2015. Defects in tRNA anticodon loop 2'-O-methylation are implicated in nonsyndromic Xlinked intellectual disability due to mutations in FTSJ1. *Hum Mutat* 36: 1176–1187.
- Hall TM. 2005. Multiple modes of RNA recognition by zinc finger proteins. *Curr Opin Struct Biol* **15:** 367–373.
- Han L, Kon Y, Phizicky EM. 2015. Functional importance of Ψ38 and Ψ39 in distinct tRNAs, amplified for tRNA^{Gln(UUG)} by unexpected temperature sensitivity of the s²U modification in yeast. *RNA* 21: 188–201.
- Helm M, Giege R, Florentz C. 1999. A Watson-Crick base-pair-disrupting methyl group (m¹A9) is sufficient for cloverleaf folding of human mitochondrial tRNA^{Lys}. *Biochemistry* **38**: 13338–13346.
- Herbert CJ, Labouesse M, Dujardin G, Slonimski PP. 1988. The NAM2 proteins from *S. cerevisiae* and *S. douglasii* are mitochondrial leucyl-tRNA synthetases, and are involved in mRNA splicing. *EMBO J* 7: 473–483.
- Himeno H, Yoshida S, Soma A, Nishikawa K. 1997. Only one nucleotide insertion to the long variable arm confers an efficient serine acceptor activity upon *Saccharomyces cerevisiae* tRNA^{Leu} in vitro. *J Mol Biol* 268: 704–711.
- Hur S, Stroud RM. 2007. How U38, 39, and 40 of many tRNAs become the targets for pseudouridylation by TruA. *Mol Cell* 26: 189–203.
 Jackman JE, Phizicky EM. 2006. tRNA^{His} guanylyltransferase adds G-1
- Jackman JE, Phizicky EM. 2006. tRNA^{His} guanylyltransferase adds G-1 to the 5' end of tRNA^{His} by recognition of the anticodon, one of several features unexpectedly shared with tRNA synthetases. *RNA* 12: 1007–1014.
- Jackman JE, Montange RK, Malik HS, Phizicky EM. 2003. Identification of the yeast gene encoding the tRNA m¹G methyltransferase responsible for modification at position 9. *RNA* **9:** 574–585.
- Janke C, Magiera MM, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E, et al. 2004. A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. *Yeast* **21**: 947–962.
- Johansson MJ, Bystrom AS. 2004. The Saccharomyces cerevisiae TAN1 gene is required for N^4 -acetylcytidine formation in tRNA. RNA **10:** 712–719.
- Johansson MJ, Esberg A, Huang B, Bjork GR, Bystrom AS. 2008. Eukaryotic wobble uridine modifications promote a functionally redundant decoding system. *Mol Cell Biol* 28: 3301–3312.
- Juhling F, Morl M, Hartmann RK, Sprinzl M, Stadler PF, Putz J. 2009. tRNAdb 2009: compilation of tRNA sequences and tRNA genes. *Nucleic Acids Res* **37**: D159–D162.
- Kadaba S, Krueger A, Trice T, Krecic AM, Hinnebusch AG, Anderson J. 2004. Nuclear surveillance and degradation of hypomodified initiator tRNA^{Met} in S. cerevisiae. Genes Dev 18: 1227–1240.
- Ledoux S, Olejniczak M, Uhlenbeck OC. 2009. A sequence element that tunes *Escherichia coli* tRNA^{Ala}_{GGC} to ensure accurate decoding. *Nat Struct Mol Biol* **16**: 359–364.
- Lu D, Searles MA, Klug A. 2003. Crystal structure of a zinc-finger-RNA complex reveals two modes of molecular recognition. *Nature* **426**: 96–100.
- Lustig F, Boren T, Claesson C, Simonsson C, Barciszewska M, Lagerkvist U. 1993. The nucleotide in position 32 of the tRNA anticodon loop determines ability of anticodon UCC to discriminate among glycine codons. *Proc Natl Acad Sci* **90**: 3343–3347.

- Macbeth MR, Schubert HL, Vandemark AP, Lingam AT, Hill CP, Bass BL. 2005. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. *Science* **309**: 1534–1539.
- Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. 2013. MODOMICS: a database of RNA modification pathways–2013 update. *Nucleic Acids Res* 41: D262–D267.
- Miyauchi K, Kimura S, Suzuki T. 2013. A cyclic form of N^6 -threonylcarbamoyladenosine as a widely distributed tRNA hypermodification. *Nat Chem Biol* **9:** 105–111.
- Moitoso de Vargas L, Pargellis CA, Hasan NM, Bushman EW, Landy A. 1988. Autonomous DNA binding domains of λ integrase recognize two different sequence families. *Cell* **54**: 923–929.
- Murphy FVt, Ramakrishnan V. 2004. Structure of a purine–purine wobble base pair in the decoding center of the ribosome. *Nat Struct Mol Biol* 11: 1251–1252.
- Na JG, Pinto I, Hampsey M. 1992. Isolation and characterization of *SUA5*, a novel gene required for normal growth in *Saccharomyces cerevisiae*. *Genetics* **131**: 791–801.
- Nakamura A, Nemoto T, Heinemann IU, Yamashita K, Sonoda T, Komoda K, Tanaka I, Soll D, Yao M. 2013. Structural basis of reverse nucleotide polymerization. *Proc Natl Acad Sci* 110: 20970–20975.
- Nolte RT, Conlin RM, Harrison SC, Brown RS. 1998. Differing roles for zinc fingers in DNA recognition: structure of a six-finger transcription factor IIIA complex. *Proc Natl Acad Sci* **95:** 2938–2943.
- Noma A, Yi S, Katoh T, Takai Y, Suzuki T, Suzuki T. 2011. Actin-binding protein ABP140 is a methyltransferase for 3-methylcytidine at position 32 of tRNAs in *Saccharomyces cerevisiae*. *RNA* **17**: 1111–1119.
- Olejniczak M, Uhlenbeck OC. 2006. tRNA residues that have coevolved with their anticodon to ensure uniform and accurate codon recognition. *Biochimie* **88**: 943–950.
- Olejniczak M, Dale T, Fahlman RP, Uhlenbeck OC. 2005. Idiosyncratic tuning of tRNAs to achieve uniform ribosome binding. *Nat Struct Mol Biol* **12:** 788–793.
- Pintard L, Lecointe F, Bujnicki JM, Bonnerot C, Grosjean H, Lapeyre B. 2002. Trm7p catalyses the formation of two 2'-O-methylriboses in yeast tRNA anticodon loop. *EMBO J* **21:** 1811–1820.
- Quartley E, Alexandrov A, Mikucki M, Buckner FS, Hol WG, DeTitta GT, Phizicky EM, Grayhack EJ. 2009. Heterologous expression of *L. major* proteins in *S. cerevisiae*: a test of solubility, purity, and gene recoding. *J Struct Funct Genomics* **10**: 233–247.
- Sampath P, Mazumder B, Seshadri V, Gerber CA, Chavatte L, Kinter M, Ting SM, Dignam JD, Kim S, Driscoll DM, et al. 2004. Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. *Cell* **119**: 195–208.
- Sarkar J, Poruri K, Boniecki MT, McTavish KK, Martinis SA. 2012. Yeast mitochondrial leucyl-tRNA synthetase CP1 domain has functionally diverged to accommodate RNA splicing at expense of hydrolytic editing. J Biol Chem 287: 14772–14781.
- Sharma S, Langhendries JL, Watzinger P, Kotter P, Entian KD, Lafontaine DL. 2015. Yeast Kre33 and human NAT10 are conserved 18S rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor Tan1/THUMPD1. *Nucleic Acids Res* **43**: 2242–2258.
- Shimada N, Suzuki T, Watanabe K. 2001. Dual mode recognition of two isoacceptor tRNAs by mammalian mitochondrial seryl-tRNA synthetase. *J Biol Chem* **276**: 46770–46778.
- Smirnova EV, Lakunina VA, Tarassov I, Krasheninnikov IA, Kamenski PA. 2012. Noncanonical functions of aminoacyl-tRNA synthetases. *Biochemistry (Mosc)* 77: 15–25.
- Swinehart WE, Jackman JE. 2015. Diversity in mechanism and function of tRNA methyltransferases. *RNA Biol* **12:** 398–411.
- Swinehart WE, Henderson JC, Jackman JE. 2013. Unexpected expansion of tRNA substrate recognition by the yeast m¹G9 methyltransferase Trm10. *RNA* **19**: 1137–1146.

- Urbonavicius J, Qian Q, Durand JM, Hagervall TG, Bjork GR. 2001. Improvement of reading frame maintenance is a common function for several tRNA modifications. *EMBO J* **20:** 4863–4873.
- Waas WF, Druzina Z, Hanan M, Schimmel P. 2007. Role of a tRNA base modification and its precursors in frameshifting in eukaryotes. J Biol Chem 282: 26026–26034.
- Wakasugi K, Schimmel P. 1999. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. *Science* 284: 147–151.
- Wang C, Guo Y, Tian Q, Jia Q, Gao Y, Zhang Q, Zhou C, Xie W. 2015. SerRS-tRNA^{Sec} complex structures reveal mechanism of the first step in selenocysteine biosynthesis. *Nucleic Acids Res* 43: 10534–10545.
- Weissenbach J, Kiraly I, Dirheimer G. 1977. Primary structure of tRNA Thr 1a and b from brewer's yeast. *Biochimie* **59:** 381–391.
- Weixlbaumer A, Murphy FVt, Dziergowska A, Malkiewicz A, Vendeix FA, Agris PF, Ramakrishnan V. 2007. Mechanism for expanding the decoding capacity of transfer RNAs by modification of uridines. *Nat Struct Mol Biol* **14**: 498–502.
- Whipple JM, Lane EA, Chernyakov I, D'Silva S, Phizicky EM. 2011. The yeast rapid tRNA decay pathway primarily monitors the structural integrity of the acceptor and T-stems of mature tRNA. *Genes Dev* **25:** 1173–1184.
- Yao P, Fox PL. 2013. Aminoacyl-tRNA synthetases in medicine and disease. *EMBO Mol Med* 5: 332–343.